View ValuationCapForce 将来の成長Future 基準チェック /06現在、 CapForceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Jan 19OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022OpGen, Inc. announced preliminary unaudited revenue for 2022. Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its third quarter earnings call.すべての更新を表示Recent updatesお知らせ • May 16CapForce Inc. announced delayed 10-Q filingOn 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01CapForce Inc. announced delayed annual 10-K filingOn 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 28OpGen, Inc., Annual General Meeting, Feb 23, 2026OpGen, Inc., Annual General Meeting, Feb 23, 2026.お知らせ • Dec 06+ 1 more updateCapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025OpGen, Inc. announced that on December 1, 2025, Mr. Christian-Laurent Bonte entered into a promotion letter with CapForce International Holdings Ltd. (CapForce), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company, pursuant to which he will serve as Chief Executive Officer of CapForce (the “Promotion Letter”). Pursuant to the Promotion Letter, Mr. Bonte’s employment may be terminated by CapForce at any time by one (1) month written notice by CapForce. Mr. Bonte, age 49, was a member of the Board until July 17, 2025, when he resigned from the Board and was appointed, pursuant to an offer letter dated June 25, 2025 (the “Offer Letter”), the Head of the Digital Investment Banking Arm of CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company. Mr. Bonte will continue to leverage his rich investment banking experience in Hong Kong and Singapore with broad in-depth Hong Kong and U.S. capital market exposure. Mr. Bonte’s experience includes serving as the Executive Director at Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, since March 2024, as the Founder and the Managing Director of Far Cap Pte Ltd, a corporate finance and technology investment firm, from December 2021 to March 2024, and as the Managing Director of ARC Capital Ltd, an investment bank with a presence in Asia and the United States, from August 2017 to December 2021. CapForce International Holdings Ltd. announced to offer Mr. Christian Bonte, the full time position of Head of Investment Banking Arm, reporting to CapForce CEO and working alongside CapForce COO. The position is offered on the following terms.お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17OpGen, Inc. announced delayed 10-Q filingOn 05/16/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01OpGen, Inc. announced delayed annual 10-K filingOn 03/31/2025, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 28OpGen Provides Nasdaq Minimum Stockholders’ Equity Requirement Non-Compliance UpdateOn December 19, 2024, despite OpGen, Inc. regaining short-term compliance with the minimum stockholders' equity requirement of the Nasdaq Capital Market (Nasdaq") pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the Listing Council") affirmed the decision of the Nasdaq Hearings Panel (the Panel"). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel's determination to effect a trading suspension and delisting of the Company's securities based upon the Company's continued non-compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the Stockholders' Equity Rule"). While the trading suspension was effective as of August 20, 2024, the Company had appealed the Panel's decision to the Listing Council. Although the Company continues to disagree with the Listing Council's decision, as a result of such decision, unless Nasdaq's Board of Directors determines to review such decision pursuant to Nasdaq Listing Rule 5825, Nasdaq will ultimately file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the Commission") that will remove the Company's securities from listing on Nasdaq. The filing of the Form 25 had been stayed pending the Company's appeal of the Panel's decision to the Listing Council. The Company's shares of common stock will continue trading on the OTC Markets under the symbol OPGN" following the filing of the Form 25 with the Commission. Consistent with the Listing Council's decision, the Listing Council welcomes the Company's application for relisting and the Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 23+ 1 more updateOpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on NasdaqAs previously disclosed on June 11, 2024, OpGen, Inc. (the ‘Company’) received a letter from the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the ‘Stockholders’ Equity Rule’). The Stockholders’ Equity Rule requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet alternatives of market value of listed securities or net income from continuing operations, which the Company does not currently meet. In response to the letter, the Company submitted its plan to regain compliance with the Stockholders’ Equity Rule to the Nasdaq Hearings Panel (the ‘Panel’) and requested additional time to regain compliance with such rule. On August 16, 2024, following the Panel’s review of the Company’s plan to regain compliance, the Company received a letter (the ‘Notice’) indicating that the Panel had determined to deny the Company’s request for continued listing on Nasdaq. Pursuant to the Notice, based on the preliminary nature of the Company’s plan, the Panel determined that the Company did not provide a definitive plan evidencing its ability to achieve near- and long-term compliance with the Stockholders’ Equity Requirement. Unless the Company requests an appeal of the Panel’s determination by August 31, 2024, Nasdaq will file a Form 25 Notification of Delisting with the SEC, which will remove the Company’s securities from listing on the Nasdaq Capital Market. The Notice also provided that the Company’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on August 20, 2024. The Company currently intends to timely appeal this determination by requesting that the Nasdaq Listing and Hearing Review Council review the decision of the Panel. Such appeal will stay the delisting of the Company’s securities with Nasdaq and the filing of the Form 25 pending the Panel’s decision until the resolution of such review. There can be no assurance that the Nasdaq Listing and Hearing Review Council will grant the Company’s request for continued listing on Nasdaq. The Company continues to pursue various steps to regain compliance with the Stockholders’ Equity Rule. Most recently, on August 19, 2024, pursuant to the previously disclosed settlement agreements (the ‘Settlement Agreements’) with each of the European Investment Bank, the Company’s senior creditor (the ‘EIB’), and Curetis GmbH, the Company’s subsidiary in insolvency (‘Curetis’), the Company paid and settled its outstanding indebtedness with the EIB and Curetis. The settlement agreement with the EIB also terminated that certain Guarantee and Indemnity Agreement, dated as of July 9, 2024 (the ‘Guarantee Agreement’), by and between the Company and EIB, pursuant to which the Company had guaranteed all of Curetis’ debt to EIB. The foregoing description of the Settlement Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of such Settlement Agreements, which are filed as Exhibits 10.2 and 10.3, respectively, to this Current Report on Form 8-K and incorporated herein by reference. In addition, as described in Item 1.01 of this Current Report on Form 8-K, the Company entered into the Purchase Agreement on August 22, 2024, pursuant to which the Company may sell the Shares for aggregate gross proceeds of up to $3,000,000. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. As a result of such settlements and the Financing, the Company expects its increased stockholders’ equity will result in the Company regaining compliance with the Stockholders’ Equity Rule. The Company plans to pursue further steps to cause the Company to maintain ongoing compliance with the Stockholders’ Equity Rule. Notwithstanding the foregoing, there can be no assurance that the Company will be successful in its efforts to regain and maintain such compliance.お知らせ • Aug 22OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI IndexOpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Indexお知らせ • Aug 21OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite IndexOpGen, Inc. has been dropped from the Nasdaq Composite Index.お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 13OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on NasdaqAs previously disclosed, the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) notified OpGen, Inc. (the ‘Company’) on June 5, 2023 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In December 2023, the Company appealed such determination to a Nasdaq Hearings Panel, which in February 2024, granted the Company’s request for an additional period to regain compliance with the Minimum Bid Price Rule. On June 5, 2024, the Nasdaq Hearings Panel notified the Company that it had regained compliance with the Minimum Bid Price Rule. In addition, on June 5, 2024, the Company received a notice from Nasdaq stating that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet the alternatives of market value of listed securities or net income from continuing operations. The notice indicated that such delinquency serves as an additional basis for delisting the Company’s securities from Nasdaq. In accordance with the notice, the Company submitted its response to the Nasdaq Hearings Panel on June 11, 2024 regarding such delinquency and the Company’s plan to cure such delinquency. As with the prior notices received by the Company, the most recent notice from Nasdaq has no immediate effect on the listing of the Company’s securities on The Nasdaq Capital Market. There can be no assurance that the Nasdaq Hearings Panel will grant the Company additional time to cure such deficiency or, if additional time is granted, that the Company will be able to regain compliance with the requirements for continued listing.お知らせ • Jun 05Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024As previously disclosed in a Current Report on Form 8-K filed on May 24, 2024, OpGen, Inc. (the Company") received an additional notice from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the Form 10-Q") and was therefore not in compliance with Nasdaq Listing Rule 5250(c)(1). Following submission of the Company's plan to cure such delinquency, on May 29, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing subject to the Company filing its Form 10-Q by July 8, 2024. The Company plans to file its Form 10-Q as soon as practicable; however, no assurance can be given as to the definitive date on which such report will be filed.お知らせ • May 25OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024OpGen, Inc. (‘OpGen’ or ‘the Company’) announced that it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the ‘Form 10-Q’), which serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company’s securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the ‘SEC’). The Company previously received written notices from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period (the ‘Minimum Bid Price Rule’) and Nasdaq Listing Rule 5250(c)(1) for failing to timely file its Annual Report on Form 10-K for the period ended December 31, 2023 (the ‘Periodic Filing Rule’). As previously disclosed, the Company received written notice from Nasdaq that a Nasdaq Hearings Panel had granted the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule and the Periodic Filing Rule. The most recent notice provides that the Nasdaq Hearings Panel will consider the delinquent Form 10-Q in connection with its prior grant of such additional period to regain compliance. The Company has been in communication with Nasdaq to request that the Nasdaq Hearings Panel continue to permit the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule and file the Company’s Form 10-K and for additional time to regain compliance with the Periodic Filing Rule. The notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. While the Company can provide no assurance as to timing, the Company is working diligently to finalize the Form 10-Q and plans to file the Form 10-Q as soon as practicable to regain compliance with the Nasdaq Listing Rule.お知らせ • May 18OpGen, Inc. announced delayed 10-Q filingOn 05/17/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per ShareOpGen, Inc. (“OpGen” or “the Company”) announced that the Company’s board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol “OPGN.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special Meeting held on May 9, 2024, will increase the market price per share of common stock in order to regain compliance with The Nasdaq Capital Market’s minimum bid price listing requirement of $1.00 per share.お知らせ • Apr 24OpGen Receives Nasdaq Notice Regarding Delayed Form 10-KOpGen, Inc. (‘OpGen’ or ‘the Company’) announced that it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the ‘Form 10-K’). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the ‘SEC’). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense. The Company previously received written notices from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period (the ‘Minimum Bid Price Rule’). As previously disclosed, on February 9, 2024, the Company received written notice from Nasdaq that a Nasdaq Hearings Panel had granted the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule. The most recent notice provides that the Nasdaq Hearings Panel will consider the delinquent Form 10-K in connection with its prior grant of an additional period to regain compliance. If the Nasdaq Hearings Panel continues to permit the Company the additional period to regain compliance, the Company expects that it will be required by Nasdaq to file the Form 10-K no later than June 3, 2024 to avoid a delisting determination. The notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq. While the Company can provide no assurance as to timing, the Company is working diligently to finalize the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Nasdaq Listing Rule.お知らせ • Mar 31OpGen, Inc. announced delayed annual 10-K filingOn 03/29/2024, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 27Opgen, Inc. Announces Chief Executive Officer ChangesOpGen, Inc. announced that David E. Lazar will be appointed as CEO following the initial closing of transaction closing as Oliver Schacht, PhD, resigned as CEO. Mr. Schacht will continue to serve as Executive Vice President of Corporate Development to assist with the transition period following the transactions. David E. Lazar is an experienced private investor who brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital restructuring, debt financing, and mergers and acquisitions.New Risk • Mar 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Market cap is less than US$10m (US$4.76m market cap). Minor Risk Revenue is less than US$5m (US$3.1m revenue).New Risk • Mar 22New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Market cap is less than US$10m (US$5.13m market cap). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (US$3.1m revenue).お知らせ • Dec 13OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel ExpiresAs previously disclosed by OpGen, Inc. (the Company"), on June 5, 2023, the listing staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notified the Company that the Company's common stock had failed to maintain aminimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Rule"). In accordance with Nasdaq ListingRule 5810(c)(3)(A), the Company was provided 180 calendar days, or until December 4, 2023, to regain compliance. On December 6, 2023, the Company received written notification (the December Notice") from the Staff indicating that, based upon (i) the Company's continued non-compliance with the Minimum Bid Price Rule and (ii) the Company's inability to meet Nasdaq's initial listing requirement for maintaining a minimum of stockholders' equity, the Staff determined that the Company was not eligible for an additional 180 day extension to meet the Minimum Bid Price Rule. As a result, the Staff determined to delist the Company's securities from Nasdaq, effective December 15, 2023, unless the Company timely requested an appeal to a Nasdaq Hearings Panel (the Panel"). On December 11, 2023, the Company submitted a request for a hearing before the Panel, which request stayed any suspension or delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires. Subject to the Panel's availability, the hearing is expected to occur in the first quarter of 2024. As a result of the pending appeal, the December Notice has no immediate effect on the listing of the Company's common stock at this time. At the hearing, the Company intends to present a plan to regain compliance with the Minimum Bid Price Rule and request that the Panel allow the Company additional time within which to regain compliance. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol OPGN" pending the outcome of the hearing. Although the Company intends to submit a comprehensive plan to regain compliance, there can be no assurances that the Panel will grant the Company's request for continued listing or that the Company will be able to demonstrate compliance with all applicable requirements for continued listing on The Nasdaq Capital Market within any extension of time that may be granted by the Panel. If the Company's common stock is delisted, it could be more difficult to buy or sell the Company's common stock or to obtain accurate quotations, and the price of the Company's common stock could suffer a material decline. Delisting could also impair the Company's ability to raise capital.Reported Earnings • Nov 17Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: US$0.46 loss per share (improved from US$5.92 loss in 3Q 2022). Revenue: US$699.0k (up 56% from 3Q 2022). Net loss: US$4.06m (loss narrowed 71% from 3Q 2022). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 7.0%. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in the US.お知らせ • Oct 12OpGen, Inc. announced that it expects to receive $1 million in fundingOpGen, Inc. announced that it has entered into a Preferred Stock Purchase Agreement with a single investor pursuant to which the company agreed to issue 1,000 shares of the Company’s Series D Preferred Stock, par value $0.01 per share at a price of $1,000 per share for aggregate gross proceeds of $1 million before deducting offering expenses on October 11, 2023. The transaction is expected to close on or about October 13, 2023.New Risk • Aug 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$21m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (215% increase in shares outstanding). Market cap is less than US$10m (US$1.95m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$22m net loss next year). Revenue is less than US$5m (US$2.8m revenue).Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: US$0.93 loss per share (improved from US$2.51 loss in 2Q 2022). Revenue: US$736.1k (down 24% from 2Q 2022). Net loss: US$5.83m (flat on 2Q 2022). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 31%. Revenue is forecast to grow 54% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in the US.お知らせ • Aug 04OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023OpGen, Inc. announced that they will report Q2, 2023 results at 12:30 PM, US Eastern Standard Time on Aug 10, 2023お知らせ • Jun 12OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price RequirementOn June 5, 2023, OpGen, Inc. received written notice from The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share over the prior 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq’s Listing Rules, the Company has 180 calendar days to regain compliance with Nasdaq’s minimum bid price requirement. If the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days if the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, if the Company provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period.Reported Earnings • May 16First quarter 2023 earnings released: US$1.25 loss per share (vs US$2.93 loss in 1Q 2022)First quarter 2023 results: US$1.25 loss per share (improved from US$2.93 loss in 1Q 2022). Revenue: US$913.4k (up 95% from 1Q 2022). Net loss: US$5.74m (loss narrowed 16% from 1Q 2022). Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US.お知らせ • May 09OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023OpGen, Inc. announced that they will report Q1, 2023 results at 4:30 PM, US Eastern Standard Time on May 15, 2023お知らせ • May 06OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,495,825 Price\Range: $0.7785 Security Name: Common Warrants Security Type: Equity Warrant Securities Offered: 4,495,825Reported Earnings • Mar 31Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$15.27 loss per share (improved from US$22.89 loss in FY 2021). Revenue: US$2.61m (down 40% from FY 2021). Net loss: US$37.3m (loss narrowed 11% from FY 2021). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 18%.Board Change • Mar 29High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 5 experienced directors. No highly experienced directors. Member of Clinical Advisory Board Stefan Riedel is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jan 19OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022OpGen, Inc. announced preliminary unaudited revenue for 2022. Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its third quarter earnings call.お知らせ • Jan 09OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,586,207 Security Name: Series A-1 Warrants Security Type: Equity Warrant Securities Offered: 2,586,207 Security Name: Series A-2 Warrants Security Type: Equity Warrant Securities Offered: 2,586,207 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 2,586,207Seeking Alpha • Sep 30OpGen to raise $3.38M in direct stock offeringOpGen (NASDAQ:OPGN) announced Friday it has signed a $3.38M securities purchase deal with a single institutional investor. It includes the the direct offering of 9,660,000 shares of OpGen (OPGN), 33,810 shares of its Series C mirroring preferred stock, and warrants to purchase up to same number of shares, at a combined purchase price of $0.35 each. Warrants have an exercise price of $0.377 per share and and will expire in five and one-half years. The management said, "the company intends to use the net proceeds to (i) continue commercialization of the FDA-cleared Acuitas AMR Gene Panel test for isolates in the U.S.; (ii) commercialize our other products with a focus on the Unyvero platform and diagnostic tests; (iii) support further development and commercialization of the Ares Genetics database; among other investments" Closing of the offering is expected on Oct. 3, 2022. OPGN shares are down 14% in pre-market on Friday. Earlier: OpGen's subsidiary signs R&D agreement with FINDSeeking Alpha • Sep 20OpGen's subsidiary signs R&D agreement with FINDOpGen's (NASDAQ:OPGN) German subsidiary Curetis has signed an R&D collaboration agreement with global diagnostics alliance FIND. The collaboration is focused on demonstrating the capabilities of OpGen's Unyvero A30 RQ platform for use in low and middle income countries for rapid detection of antimicrobial resistance (AMR). During the anticipated feasibility project, Curetis' R&D team will strive to develop a molecular test panel with a comprehensive set of pathogen ID and AMR detection assays, develop an easy to perform workflow compatible with available blood culture systems in target regions and to adapt some key features of the A30 RQ platform important for use in environments often found in LMICs. If successful, both parties have agreed to discuss the option of a potential future collaboration and commercialization agreement. Such future collaboration agreement would aim to bring the Unyvero A30 RQ platform and initial application products through required clinical studies and regulatory approvals in LMICs to make them commercially available at an attractive cost profile to commercial distribution partners. OPGN shares have gained 9% pre-marketSeeking Alpha • Aug 31Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirementThe Nasdaq has granted to the medicine company OpGen (NASDAQ:OPGN) a 180-day extension to regain compliance with the stock exchange's minimum bid price requirement. OpGen now has until Feb. 27, 2023, to regain compliance. The compliance will be regained if at any time until Feb. 27, 2023, the bid price per share closes at or above $1.00 for a minimum of 10 consecutive trading days. OPGN shares were trading -0.60% pre-market. Source: Press ReleaseSeeking Alpha • Aug 25OpGen launches sequencing services for infectious diseases in USOpGen (NASDAQ:OPGN) said it launched next generation sequencing services in the U.S. for use infectious diseases. The services, which are developed by OpGen's unit Ares Genetics, will provide the infectious disease community in the U.S. with routine sequencing of priority isolates and outbreak analyses that support their needs for surveillance, infection prevention and antibiotic stewardship, the company OpGen noted that the Rockville-based laboratory's services at launch include rapid turnaround sequencing of clinical isolates, differentiated interpretative services and a web application called AREScloud for outbreak analysis.Seeking Alpha • Aug 11OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-lineOpGen press release (NASDAQ:OPGN): Q2 GAAP EPS of -$0.13 beats by $0.02. Revenue of $1M (+23.5% Y/Y) in-line.Seeking Alpha • Jul 08OpGen reports preliminary revenue estimate for Q2 2022OpGen (NASDAQ:OPGN) announced Friday the preliminary second quarter estimates with revenue expected to be $1M, up from $0.8M in prior year. "We are excited by the progress made in the second quarter, especially the fact that in June we signed the first commercial contract for our Acuitas AMR Gene Panel in the U.S. with a major hospital in the Northeast, the expansion of our distribution partnership with Menarini with significantly increased annual minimum revenue commitments by Menarini along with the agreement whereby Menarini has purchased the entire European pool of Unyvero systems across 9 countries from us at residual fair market value," stated President and CEO Oliver Schacht. Cash as of June 30, 2022 was approximately $16.6M. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、CapForce は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:CFOR - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20253023-1-1N/A9/30/202597-1-1N/A6/30/2025916-4-4N/A3/31/2025511-4-4N/A12/31/2024511-5-5N/A9/30/20241-10-6-6N/A6/30/20242-22-7-6N/A3/31/20243-27-11-10N/A12/31/20233-33-15-14N/A9/30/20233-26-18-17N/A6/30/20233-36-20-18N/A3/31/20233-36-21-20N/A12/31/20223-37-21-20N/A9/30/20223-41-21-20N/A6/30/20224-33-21-21N/A3/31/20224-34-23-22N/A12/31/20214-42-23-21N/A9/30/20214-35-27-25N/A6/30/20214-37-29-27N/A3/31/20214-37-27-26N/A12/31/20204-26-24-23N/A9/30/20204-22-20-20N/A6/30/20203-17-15-15N/A3/31/20203-13-11-11N/A12/31/20193-12-12-12N/A9/30/20193-14N/A-11N/A6/30/20193-13N/A-11N/A3/31/20193-14N/A-12N/A12/31/20183-13N/A-11N/A9/30/20183-13N/A-11N/A6/30/20183-13N/A-12N/A3/31/20183-13N/A-12N/A12/31/20173-15N/A-14N/A9/30/20173-17N/A-16N/A6/30/20173-19N/A-16N/A3/31/20174-20N/A-18N/A12/31/20164-19N/A-17N/A9/30/20164-19N/A-16N/A6/30/20165-19N/A-19N/A3/31/20164-19N/A-16N/A12/31/20153-18N/A-14N/A9/30/20153-14N/A-13N/A6/30/20153-12N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CFORの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CFORの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CFORの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CFORの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CFORの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CFORの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 19:14終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CapForce Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Benjamin HaynorAlliance Global Partnersnull nullBrookline Capital MarketsNidhi SinghEdison Investment Research2 その他のアナリストを表示
お知らせ • Jan 19OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022OpGen, Inc. announced preliminary unaudited revenue for 2022. Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its third quarter earnings call.
お知らせ • May 16CapForce Inc. announced delayed 10-Q filingOn 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01CapForce Inc. announced delayed annual 10-K filingOn 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 28OpGen, Inc., Annual General Meeting, Feb 23, 2026OpGen, Inc., Annual General Meeting, Feb 23, 2026.
お知らせ • Dec 06+ 1 more updateCapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025OpGen, Inc. announced that on December 1, 2025, Mr. Christian-Laurent Bonte entered into a promotion letter with CapForce International Holdings Ltd. (CapForce), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company, pursuant to which he will serve as Chief Executive Officer of CapForce (the “Promotion Letter”). Pursuant to the Promotion Letter, Mr. Bonte’s employment may be terminated by CapForce at any time by one (1) month written notice by CapForce. Mr. Bonte, age 49, was a member of the Board until July 17, 2025, when he resigned from the Board and was appointed, pursuant to an offer letter dated June 25, 2025 (the “Offer Letter”), the Head of the Digital Investment Banking Arm of CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company. Mr. Bonte will continue to leverage his rich investment banking experience in Hong Kong and Singapore with broad in-depth Hong Kong and U.S. capital market exposure. Mr. Bonte’s experience includes serving as the Executive Director at Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, since March 2024, as the Founder and the Managing Director of Far Cap Pte Ltd, a corporate finance and technology investment firm, from December 2021 to March 2024, and as the Managing Director of ARC Capital Ltd, an investment bank with a presence in Asia and the United States, from August 2017 to December 2021. CapForce International Holdings Ltd. announced to offer Mr. Christian Bonte, the full time position of Head of Investment Banking Arm, reporting to CapForce CEO and working alongside CapForce COO. The position is offered on the following terms.
お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17OpGen, Inc. announced delayed 10-Q filingOn 05/16/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01OpGen, Inc. announced delayed annual 10-K filingOn 03/31/2025, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 28OpGen Provides Nasdaq Minimum Stockholders’ Equity Requirement Non-Compliance UpdateOn December 19, 2024, despite OpGen, Inc. regaining short-term compliance with the minimum stockholders' equity requirement of the Nasdaq Capital Market (Nasdaq") pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the Listing Council") affirmed the decision of the Nasdaq Hearings Panel (the Panel"). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel's determination to effect a trading suspension and delisting of the Company's securities based upon the Company's continued non-compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the Stockholders' Equity Rule"). While the trading suspension was effective as of August 20, 2024, the Company had appealed the Panel's decision to the Listing Council. Although the Company continues to disagree with the Listing Council's decision, as a result of such decision, unless Nasdaq's Board of Directors determines to review such decision pursuant to Nasdaq Listing Rule 5825, Nasdaq will ultimately file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the Commission") that will remove the Company's securities from listing on Nasdaq. The filing of the Form 25 had been stayed pending the Company's appeal of the Panel's decision to the Listing Council. The Company's shares of common stock will continue trading on the OTC Markets under the symbol OPGN" following the filing of the Form 25 with the Commission. Consistent with the Listing Council's decision, the Listing Council welcomes the Company's application for relisting and the Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.
お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 23+ 1 more updateOpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on NasdaqAs previously disclosed on June 11, 2024, OpGen, Inc. (the ‘Company’) received a letter from the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the ‘Stockholders’ Equity Rule’). The Stockholders’ Equity Rule requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet alternatives of market value of listed securities or net income from continuing operations, which the Company does not currently meet. In response to the letter, the Company submitted its plan to regain compliance with the Stockholders’ Equity Rule to the Nasdaq Hearings Panel (the ‘Panel’) and requested additional time to regain compliance with such rule. On August 16, 2024, following the Panel’s review of the Company’s plan to regain compliance, the Company received a letter (the ‘Notice’) indicating that the Panel had determined to deny the Company’s request for continued listing on Nasdaq. Pursuant to the Notice, based on the preliminary nature of the Company’s plan, the Panel determined that the Company did not provide a definitive plan evidencing its ability to achieve near- and long-term compliance with the Stockholders’ Equity Requirement. Unless the Company requests an appeal of the Panel’s determination by August 31, 2024, Nasdaq will file a Form 25 Notification of Delisting with the SEC, which will remove the Company’s securities from listing on the Nasdaq Capital Market. The Notice also provided that the Company’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on August 20, 2024. The Company currently intends to timely appeal this determination by requesting that the Nasdaq Listing and Hearing Review Council review the decision of the Panel. Such appeal will stay the delisting of the Company’s securities with Nasdaq and the filing of the Form 25 pending the Panel’s decision until the resolution of such review. There can be no assurance that the Nasdaq Listing and Hearing Review Council will grant the Company’s request for continued listing on Nasdaq. The Company continues to pursue various steps to regain compliance with the Stockholders’ Equity Rule. Most recently, on August 19, 2024, pursuant to the previously disclosed settlement agreements (the ‘Settlement Agreements’) with each of the European Investment Bank, the Company’s senior creditor (the ‘EIB’), and Curetis GmbH, the Company’s subsidiary in insolvency (‘Curetis’), the Company paid and settled its outstanding indebtedness with the EIB and Curetis. The settlement agreement with the EIB also terminated that certain Guarantee and Indemnity Agreement, dated as of July 9, 2024 (the ‘Guarantee Agreement’), by and between the Company and EIB, pursuant to which the Company had guaranteed all of Curetis’ debt to EIB. The foregoing description of the Settlement Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of such Settlement Agreements, which are filed as Exhibits 10.2 and 10.3, respectively, to this Current Report on Form 8-K and incorporated herein by reference. In addition, as described in Item 1.01 of this Current Report on Form 8-K, the Company entered into the Purchase Agreement on August 22, 2024, pursuant to which the Company may sell the Shares for aggregate gross proceeds of up to $3,000,000. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. As a result of such settlements and the Financing, the Company expects its increased stockholders’ equity will result in the Company regaining compliance with the Stockholders’ Equity Rule. The Company plans to pursue further steps to cause the Company to maintain ongoing compliance with the Stockholders’ Equity Rule. Notwithstanding the foregoing, there can be no assurance that the Company will be successful in its efforts to regain and maintain such compliance.
お知らせ • Aug 22OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI IndexOpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index
お知らせ • Aug 21OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite IndexOpGen, Inc. has been dropped from the Nasdaq Composite Index.
お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 13OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on NasdaqAs previously disclosed, the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) notified OpGen, Inc. (the ‘Company’) on June 5, 2023 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In December 2023, the Company appealed such determination to a Nasdaq Hearings Panel, which in February 2024, granted the Company’s request for an additional period to regain compliance with the Minimum Bid Price Rule. On June 5, 2024, the Nasdaq Hearings Panel notified the Company that it had regained compliance with the Minimum Bid Price Rule. In addition, on June 5, 2024, the Company received a notice from Nasdaq stating that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet the alternatives of market value of listed securities or net income from continuing operations. The notice indicated that such delinquency serves as an additional basis for delisting the Company’s securities from Nasdaq. In accordance with the notice, the Company submitted its response to the Nasdaq Hearings Panel on June 11, 2024 regarding such delinquency and the Company’s plan to cure such delinquency. As with the prior notices received by the Company, the most recent notice from Nasdaq has no immediate effect on the listing of the Company’s securities on The Nasdaq Capital Market. There can be no assurance that the Nasdaq Hearings Panel will grant the Company additional time to cure such deficiency or, if additional time is granted, that the Company will be able to regain compliance with the requirements for continued listing.
お知らせ • Jun 05Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024As previously disclosed in a Current Report on Form 8-K filed on May 24, 2024, OpGen, Inc. (the Company") received an additional notice from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the Form 10-Q") and was therefore not in compliance with Nasdaq Listing Rule 5250(c)(1). Following submission of the Company's plan to cure such delinquency, on May 29, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing subject to the Company filing its Form 10-Q by July 8, 2024. The Company plans to file its Form 10-Q as soon as practicable; however, no assurance can be given as to the definitive date on which such report will be filed.
お知らせ • May 25OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024OpGen, Inc. (‘OpGen’ or ‘the Company’) announced that it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the ‘Form 10-Q’), which serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company’s securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the ‘SEC’). The Company previously received written notices from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period (the ‘Minimum Bid Price Rule’) and Nasdaq Listing Rule 5250(c)(1) for failing to timely file its Annual Report on Form 10-K for the period ended December 31, 2023 (the ‘Periodic Filing Rule’). As previously disclosed, the Company received written notice from Nasdaq that a Nasdaq Hearings Panel had granted the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule and the Periodic Filing Rule. The most recent notice provides that the Nasdaq Hearings Panel will consider the delinquent Form 10-Q in connection with its prior grant of such additional period to regain compliance. The Company has been in communication with Nasdaq to request that the Nasdaq Hearings Panel continue to permit the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule and file the Company’s Form 10-K and for additional time to regain compliance with the Periodic Filing Rule. The notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. While the Company can provide no assurance as to timing, the Company is working diligently to finalize the Form 10-Q and plans to file the Form 10-Q as soon as practicable to regain compliance with the Nasdaq Listing Rule.
お知らせ • May 18OpGen, Inc. announced delayed 10-Q filingOn 05/17/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per ShareOpGen, Inc. (“OpGen” or “the Company”) announced that the Company’s board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol “OPGN.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special Meeting held on May 9, 2024, will increase the market price per share of common stock in order to regain compliance with The Nasdaq Capital Market’s minimum bid price listing requirement of $1.00 per share.
お知らせ • Apr 24OpGen Receives Nasdaq Notice Regarding Delayed Form 10-KOpGen, Inc. (‘OpGen’ or ‘the Company’) announced that it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the ‘Form 10-K’). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the ‘SEC’). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense. The Company previously received written notices from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period (the ‘Minimum Bid Price Rule’). As previously disclosed, on February 9, 2024, the Company received written notice from Nasdaq that a Nasdaq Hearings Panel had granted the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule. The most recent notice provides that the Nasdaq Hearings Panel will consider the delinquent Form 10-K in connection with its prior grant of an additional period to regain compliance. If the Nasdaq Hearings Panel continues to permit the Company the additional period to regain compliance, the Company expects that it will be required by Nasdaq to file the Form 10-K no later than June 3, 2024 to avoid a delisting determination. The notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq. While the Company can provide no assurance as to timing, the Company is working diligently to finalize the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Nasdaq Listing Rule.
お知らせ • Mar 31OpGen, Inc. announced delayed annual 10-K filingOn 03/29/2024, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 27Opgen, Inc. Announces Chief Executive Officer ChangesOpGen, Inc. announced that David E. Lazar will be appointed as CEO following the initial closing of transaction closing as Oliver Schacht, PhD, resigned as CEO. Mr. Schacht will continue to serve as Executive Vice President of Corporate Development to assist with the transition period following the transactions. David E. Lazar is an experienced private investor who brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital restructuring, debt financing, and mergers and acquisitions.
New Risk • Mar 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Market cap is less than US$10m (US$4.76m market cap). Minor Risk Revenue is less than US$5m (US$3.1m revenue).
New Risk • Mar 22New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (94% increase in shares outstanding). Market cap is less than US$10m (US$5.13m market cap). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (US$3.1m revenue).
お知らせ • Dec 13OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel ExpiresAs previously disclosed by OpGen, Inc. (the Company"), on June 5, 2023, the listing staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notified the Company that the Company's common stock had failed to maintain aminimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Rule"). In accordance with Nasdaq ListingRule 5810(c)(3)(A), the Company was provided 180 calendar days, or until December 4, 2023, to regain compliance. On December 6, 2023, the Company received written notification (the December Notice") from the Staff indicating that, based upon (i) the Company's continued non-compliance with the Minimum Bid Price Rule and (ii) the Company's inability to meet Nasdaq's initial listing requirement for maintaining a minimum of stockholders' equity, the Staff determined that the Company was not eligible for an additional 180 day extension to meet the Minimum Bid Price Rule. As a result, the Staff determined to delist the Company's securities from Nasdaq, effective December 15, 2023, unless the Company timely requested an appeal to a Nasdaq Hearings Panel (the Panel"). On December 11, 2023, the Company submitted a request for a hearing before the Panel, which request stayed any suspension or delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires. Subject to the Panel's availability, the hearing is expected to occur in the first quarter of 2024. As a result of the pending appeal, the December Notice has no immediate effect on the listing of the Company's common stock at this time. At the hearing, the Company intends to present a plan to regain compliance with the Minimum Bid Price Rule and request that the Panel allow the Company additional time within which to regain compliance. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol OPGN" pending the outcome of the hearing. Although the Company intends to submit a comprehensive plan to regain compliance, there can be no assurances that the Panel will grant the Company's request for continued listing or that the Company will be able to demonstrate compliance with all applicable requirements for continued listing on The Nasdaq Capital Market within any extension of time that may be granted by the Panel. If the Company's common stock is delisted, it could be more difficult to buy or sell the Company's common stock or to obtain accurate quotations, and the price of the Company's common stock could suffer a material decline. Delisting could also impair the Company's ability to raise capital.
Reported Earnings • Nov 17Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: US$0.46 loss per share (improved from US$5.92 loss in 3Q 2022). Revenue: US$699.0k (up 56% from 3Q 2022). Net loss: US$4.06m (loss narrowed 71% from 3Q 2022). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 7.0%. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in the US.
お知らせ • Oct 12OpGen, Inc. announced that it expects to receive $1 million in fundingOpGen, Inc. announced that it has entered into a Preferred Stock Purchase Agreement with a single investor pursuant to which the company agreed to issue 1,000 shares of the Company’s Series D Preferred Stock, par value $0.01 per share at a price of $1,000 per share for aggregate gross proceeds of $1 million before deducting offering expenses on October 11, 2023. The transaction is expected to close on or about October 13, 2023.
New Risk • Aug 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$21m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (215% increase in shares outstanding). Market cap is less than US$10m (US$1.95m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$22m net loss next year). Revenue is less than US$5m (US$2.8m revenue).
Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: US$0.93 loss per share (improved from US$2.51 loss in 2Q 2022). Revenue: US$736.1k (down 24% from 2Q 2022). Net loss: US$5.83m (flat on 2Q 2022). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 31%. Revenue is forecast to grow 54% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in the US.
お知らせ • Aug 04OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023OpGen, Inc. announced that they will report Q2, 2023 results at 12:30 PM, US Eastern Standard Time on Aug 10, 2023
お知らせ • Jun 12OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price RequirementOn June 5, 2023, OpGen, Inc. received written notice from The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share over the prior 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq’s Listing Rules, the Company has 180 calendar days to regain compliance with Nasdaq’s minimum bid price requirement. If the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days if the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, if the Company provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period.
Reported Earnings • May 16First quarter 2023 earnings released: US$1.25 loss per share (vs US$2.93 loss in 1Q 2022)First quarter 2023 results: US$1.25 loss per share (improved from US$2.93 loss in 1Q 2022). Revenue: US$913.4k (up 95% from 1Q 2022). Net loss: US$5.74m (loss narrowed 16% from 1Q 2022). Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US.
お知らせ • May 09OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023OpGen, Inc. announced that they will report Q1, 2023 results at 4:30 PM, US Eastern Standard Time on May 15, 2023
お知らせ • May 06OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,495,825 Price\Range: $0.7785 Security Name: Common Warrants Security Type: Equity Warrant Securities Offered: 4,495,825
Reported Earnings • Mar 31Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$15.27 loss per share (improved from US$22.89 loss in FY 2021). Revenue: US$2.61m (down 40% from FY 2021). Net loss: US$37.3m (loss narrowed 11% from FY 2021). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 18%.
Board Change • Mar 29High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 5 experienced directors. No highly experienced directors. Member of Clinical Advisory Board Stefan Riedel is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 19OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022OpGen, Inc. announced preliminary unaudited revenue for 2022. Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its third quarter earnings call.
お知らせ • Jan 09OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,586,207 Security Name: Series A-1 Warrants Security Type: Equity Warrant Securities Offered: 2,586,207 Security Name: Series A-2 Warrants Security Type: Equity Warrant Securities Offered: 2,586,207 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 2,586,207
Seeking Alpha • Sep 30OpGen to raise $3.38M in direct stock offeringOpGen (NASDAQ:OPGN) announced Friday it has signed a $3.38M securities purchase deal with a single institutional investor. It includes the the direct offering of 9,660,000 shares of OpGen (OPGN), 33,810 shares of its Series C mirroring preferred stock, and warrants to purchase up to same number of shares, at a combined purchase price of $0.35 each. Warrants have an exercise price of $0.377 per share and and will expire in five and one-half years. The management said, "the company intends to use the net proceeds to (i) continue commercialization of the FDA-cleared Acuitas AMR Gene Panel test for isolates in the U.S.; (ii) commercialize our other products with a focus on the Unyvero platform and diagnostic tests; (iii) support further development and commercialization of the Ares Genetics database; among other investments" Closing of the offering is expected on Oct. 3, 2022. OPGN shares are down 14% in pre-market on Friday. Earlier: OpGen's subsidiary signs R&D agreement with FIND
Seeking Alpha • Sep 20OpGen's subsidiary signs R&D agreement with FINDOpGen's (NASDAQ:OPGN) German subsidiary Curetis has signed an R&D collaboration agreement with global diagnostics alliance FIND. The collaboration is focused on demonstrating the capabilities of OpGen's Unyvero A30 RQ platform for use in low and middle income countries for rapid detection of antimicrobial resistance (AMR). During the anticipated feasibility project, Curetis' R&D team will strive to develop a molecular test panel with a comprehensive set of pathogen ID and AMR detection assays, develop an easy to perform workflow compatible with available blood culture systems in target regions and to adapt some key features of the A30 RQ platform important for use in environments often found in LMICs. If successful, both parties have agreed to discuss the option of a potential future collaboration and commercialization agreement. Such future collaboration agreement would aim to bring the Unyvero A30 RQ platform and initial application products through required clinical studies and regulatory approvals in LMICs to make them commercially available at an attractive cost profile to commercial distribution partners. OPGN shares have gained 9% pre-market
Seeking Alpha • Aug 31Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirementThe Nasdaq has granted to the medicine company OpGen (NASDAQ:OPGN) a 180-day extension to regain compliance with the stock exchange's minimum bid price requirement. OpGen now has until Feb. 27, 2023, to regain compliance. The compliance will be regained if at any time until Feb. 27, 2023, the bid price per share closes at or above $1.00 for a minimum of 10 consecutive trading days. OPGN shares were trading -0.60% pre-market. Source: Press Release
Seeking Alpha • Aug 25OpGen launches sequencing services for infectious diseases in USOpGen (NASDAQ:OPGN) said it launched next generation sequencing services in the U.S. for use infectious diseases. The services, which are developed by OpGen's unit Ares Genetics, will provide the infectious disease community in the U.S. with routine sequencing of priority isolates and outbreak analyses that support their needs for surveillance, infection prevention and antibiotic stewardship, the company OpGen noted that the Rockville-based laboratory's services at launch include rapid turnaround sequencing of clinical isolates, differentiated interpretative services and a web application called AREScloud for outbreak analysis.
Seeking Alpha • Aug 11OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-lineOpGen press release (NASDAQ:OPGN): Q2 GAAP EPS of -$0.13 beats by $0.02. Revenue of $1M (+23.5% Y/Y) in-line.
Seeking Alpha • Jul 08OpGen reports preliminary revenue estimate for Q2 2022OpGen (NASDAQ:OPGN) announced Friday the preliminary second quarter estimates with revenue expected to be $1M, up from $0.8M in prior year. "We are excited by the progress made in the second quarter, especially the fact that in June we signed the first commercial contract for our Acuitas AMR Gene Panel in the U.S. with a major hospital in the Northeast, the expansion of our distribution partnership with Menarini with significantly increased annual minimum revenue commitments by Menarini along with the agreement whereby Menarini has purchased the entire European pool of Unyvero systems across 9 countries from us at residual fair market value," stated President and CEO Oliver Schacht. Cash as of June 30, 2022 was approximately $16.6M.